EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Utilidad de la monitorización terapéutica de vedolizumab en el control de la respuesta en enfermedad de Crohn

Laura Moñino-Dominguez, Alicia Aguado-Paredes, Jaime Cordero-Ramos, Maria José Tirado-Pérez, Alejandro Martínez-Escudero, Federico Argüelles-Arias, Vicente Merino-Bohórquez

Medicina Clínica · 2026

DOI: 10.1016/j.medcli.2025.107254 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medicina Clínica, 2026. Verfasst von Laura Moñino-Dominguez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen Macarena, Sevilla, España. Electronic address: ezlaura@gmail.com. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized, Drug Monitoring, Gastrointestinal Agents. Die Arbeit nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The predictive value of therapeutic drug monitoring (TDM) of vedolizumab in Crohn's disease (CD) during the maintenance phase remains uncertain. This study assessed its association with clinical and biochemical remission in routine clinical practice and explored variables influencing trough concentration variability. METHODS: A retrospective observational study was conducted at a tertiary hospital between July 2022 and December 2024. Adult CD patients receiving vedolizumab during maintenance and undergoing routine TDM were included. Clinical variables (age, treatment duration, administration route, perianal disease), laboratory markers (albumin, C-reactive protein [CRP], fecal calprotectin [FCP]), and pharmacokinetic data were collected. Trough concentrations were measured using ELISA. Clinical remission was defined as a Harvey-Bradshaw Index

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, Monoclonal, HumanizedDrug MonitoringGastrointestinal AgentsHumansFemaleRetrospective StudiesMaleAdultRemission InductionMiddle AgedC-Reactive ProteinROC CurveLeukocyte L1 Antigen ComplexTreatment OutcomeBiomarkers

Stichwörter der Autor:innen

Clinical remissionConcentraciones plasmáticasCrohn's diseaseEnfermedad de CrohnMonitorización terapéuticaRemisión clínicaTherapeutic drug monitoringTrough concentrationsVedolizumab

Substanzen

Antibodies, Monoclonal, HumanizedvedolizumabGastrointestinal AgentsC-Reactive ProteinLeukocyte L1 Antigen ComplexBiomarkers

Autor:innen und Institutionen

  • Hospital Universitario Virgen Macarena, Sevilla, España. Electronic address: ezlaura@gmail.com.
  • Hospital Universitario Virgen Macarena, Sevilla, España.

Zitieren

APA

Moñino-Dominguez, L., Aguado-Paredes, A., Cordero-Ramos, J., Tirado-Pérez, M. J., Martínez-Escudero, A., Argüelles-Arias, F., & Merino-Bohórquez, V. (2026). Utilidad de la monitorización terapéutica de vedolizumab en el control de la respuesta en enfermedad de Crohn. Medicina Clínica. https://doi.org/10.1016/j.medcli.2025.107254

Vancouver

Moñino-Dominguez L, Aguado-Paredes A, Cordero-Ramos J, Tirado-Pérez MJ, Martínez-Escudero A, Argüelles-Arias F, et al. Utilidad de la monitorización terapéutica de vedolizumab en el control de la respuesta en enfermedad de Crohn. Medicina Clínica. 2026. doi:10.1016/j.medcli.2025.107254

BibTeX
@article{MoinoDominguez2026,
  author = {Moñino-Dominguez, Laura and Aguado-Paredes, Alicia and Cordero-Ramos, Jaime and Tirado-Pérez, Maria José and Martínez-Escudero, Alejandro and Argüelles-Arias, Federico and Merino-Bohórquez, Vicente},
  title = {Utilidad de la monitorización terapéutica de vedolizumab en el control de la respuesta en enfermedad de Crohn},
  journal = {Medicina Clínica},
  year = {2026},
  doi = {10.1016/j.medcli.2025.107254}
}
Kostenlos starten →